The disease course of multiple sclerosis before and during COVID-19 pandemic: A retrospective five-year study

Babtain, Fawzi; Bajafar, A.; Nazmi, Ohoud; Badawi, Manal; Basndwah, Ahmed; Bushnag, Areej; Cupler, Edward; Hassan, Ahmed O.

doi:10.1016/j.msard.2022.103985

Cited by 10 publications

(17 citation statements)

References 68 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other sources report a higher susceptibility to infection in patients with autoimmune diseases, either because of active autoimmune disease or because of the drugs used to treat them [7]. On the other hand, the results of other studies do not show an association between more severe COVID-19 trajectories in people with autoimmune diseases [6,7,87,88,90,92]. However, the results of some studies have suggested that people with autoimmune diseases may have a protective factor that would protect them from the most severe complications of COVID-19 as a result of taking medication [2,7,90].…”

Section: Covid-19 In Patients With Autoimmune Diseasesmentioning

confidence: 91%

“…It is still unclear whether or not autoimmune diseases pose a high risk of severe complications [2,6,7,14,15]. Results from some studies suggest a higher rate of hospitalisation and more complications of COVID-19 in people with autoimmune diseases and a higher mortality rate [6,14,15,24,[88][89][90][91]. People with autoimmune diseases could be more susceptible to SARS-CoV-2 infection compared with the healthy population due to impaired immune response, use of immunosuppressive drugs and damage to various organs [6,15,29].…”

Section: Covid-19 In Patients With Autoimmune Diseasesmentioning

confidence: 99%

“…Many people with autoimmune diseases who are receiving immunosuppressive drugs have stopped treatment for fear of the side effects of these drugs, which may increase susceptibility to SARS-CoV-2 infection, leading to faster viral replication, more severe symptoms and a more severe disease course [6,7,14,88]. For example, the use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with higher complication rates in SARS-CoV-2 respiratory tract infections [7,14].…”

Section: Covid-19 In Patients With Autoimmune Diseasesmentioning

confidence: 99%

“…However, these results are limited to non-COVID-19 studies. For reliable data, a study of SARS-CoV-2-infected patients treated with methotrexate would be needed [14,88]. The use of TNF-α inhibitors (etanercept, infliximab, adalimumab) is also thought to be effective in reducing the risk of developing a more severe course of COVID-19 [14].…”

Section: Covid-19 In Patients With Autoimmune Diseasesmentioning

confidence: 99%

See 3 more Smart Citations

A Review Pertaining to SARS-CoV-2 and Autoimmune Diseases: What Is the Connection?

Kocivnik

Velnar

2022

Life

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is an infectious viral disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). It is known that infection with SARS-CoV-2 can lead to various autoimmune and autoinflammatory diseases. There are few reports in the literature on the association between SARS-CoV-2 and autoimmune diseases, and the number of reports has been increasing since 2020. Autoimmune diseases and SARS-CoV-2 infections are intertwined in several ways. Both conditions lead to immune-mediated tissue damage, the immune response is accompanied by the increased secretion of inflammatory cytokines and both conditions can be treated using immunomodulatory drugs. Patients with certain autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes, cardiac sarcoidosis, idiopathic pulmonary fibrosis, autoimmune hepatitis, multiple sclerosis and others, are more susceptible to SARS-CoV-2 infection, either because of the active autoimmune disease or because of the medications used to treat it. Conversely, SARS-CoV-2 infection can also cause certain autoimmune diseases. In this paper, we describe the development of autoimmune diseases after COVID-19 and the recovery from COVID-19 in people with autoimmune diseases.

show abstract

Section: Covid-19 In Patients With Autoimmune Diseasesmentioning

confidence: 91%

Section: Covid-19 In Patients With Autoimmune Diseasesmentioning

confidence: 99%

Section: Covid-19 In Patients With Autoimmune Diseasesmentioning

confidence: 99%

Section: Covid-19 In Patients With Autoimmune Diseasesmentioning

confidence: 99%

See 2 more Smart Citations

A Review Pertaining to SARS-CoV-2 and Autoimmune Diseases: What Is the Connection?

Kocivnik

Velnar

2022

Life

View full text Add to dashboard Cite

show abstract

“…A few previous studies have investigated the relationship between SARS-CoV-2 infection and risk of new demyelinating events, or between SARS-CoV-2 infection and risk of clinical relapses in patients with MS. ( Verstrepen et al, 2020 , Yavari et al, 2020 , Corrêa et al, 2021 , Zhang et al, 2021 , Etemadifar et al, 2021 , Barzegar et al, 2021 , Garjani et al, 2021 , Michelena et al, 2022 , Ismail and Salama, 2022 , Etemadifar et al, 2022 , Bsteh et al, 2022 , Babtain et al, 2022 , Conway et al, 2022 , Kim et al, 2022 , Lotan et al, 2022 ) Many published studies were however limited to small case series, often lacked a matched control group, and did not include MRI data.…”

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2 pandemic as a model to assess the relationship between intercurrent viral infections and disease activity in Multiple Sclerosis: A propensity score matched case-control study

Vercellino

Bosa

Alteno

et al. 2023

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

Multiple sclerosis and COVID-19: a northern China survey

Guo,

Wang,

Huang

et al. 2024

Neurol Sci

View full text Add to dashboard Cite

Background There is insufficient data on severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) infection in Chinese patients with multiple sclerosis (pwMS). This study aims to explore the manifestation of pwMS during the Coronavirus disease 2019 (COVID-19) pandemic and the effect of SARS-CoV-2 infection on the prognosis of MS in northern China. Methods In this cross-sectional study, an online self-administered questionnaire and telephone interviews were conducted among pwMS of northern China. Clinical correlation of SARS-CoV-2 infection since the onset of the COVID-19 pandemic in northern China was analyzed. Results 164 patients with an average age of 38.9 ± 12.2 years were included, of which 57.3% had a disease course ≤ 5 years. 33.5% of the patients were COVID-19 vaccinated. 87.2% received disease-modifying therapy (DMT), and the average immunotherapy duration was 1.9 ± 1.6 years. 83.5% were SARS-CoV-2 infected, 14.6% reported worsening of their original condition after infection, and 5.1% had a relapse of MS. Shorter disease course was independently related to infection risk (P = 0.046), whereas increasing age was related to aggravated behavioral symptoms (P = 0.008). However, gender, vaccination, and DMT were not associated with susceptibility or poor prognosis. Conclusion A shorter disease course is independently associated with an increased risk of SARS-CoV-2 infection, and age is associated with worsening disability. It seems to be safe and necessary to use DMT during the pandemic, however, the use of B cell-depletion agents should be approached with caution.

show abstract

The disease course of multiple sclerosis before and during COVID-19 pandemic: A retrospective five-year study

Cited by 10 publications

References 68 publications

A Review Pertaining to SARS-CoV-2 and Autoimmune Diseases: What Is the Connection?

A Review Pertaining to SARS-CoV-2 and Autoimmune Diseases: What Is the Connection?

SARS-CoV-2 pandemic as a model to assess the relationship between intercurrent viral infections and disease activity in Multiple Sclerosis: A propensity score matched case-control study

Multiple sclerosis and COVID-19: a northern China survey

Contact Info

Product

Resources

About